"Benzoquinones" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Benzene rings which contain two ketone moieties in any position. They can be substituted in any position except at the ketone groups.
Below are MeSH descriptors whose meaning is more general than "Benzoquinones".
Below are MeSH descriptors whose meaning is more specific than "Benzoquinones".
This graph shows the total number of publications written about "Benzoquinones" by people in this website by year, and whether "Benzoquinones" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Benzoquinones" by people in Profiles.
Song N, Zhang MT, Binstead RA, Fang Z, Meyer TJ. Multiple pathways in the oxidation of a NADH analogue. Inorg Chem. 2014 Apr 21; 53(8):4100-5.
Song N, Gagliardi CJ, Binstead RA, Zhang MT, Thorp H, Meyer TJ. Role of proton-coupled electron transfer in the redox interconversion between benzoquinone and hydroquinone. J Am Chem Soc. 2012 Nov 14; 134(45):18538-41.
Judson PL, Al Sawah E, Marchion DC, Xiong Y, Bicaku E, Bou Zgheib N, Chon HS, Stickles XB, Hakam A, Wenham RM, Apte SM, Gonzalez-Bosquet J, Chen DT, Lancaster JM. Characterizing the efficacy of fermented wheat germ extract against ovarian cancer and defining the genomic basis of its activity. Int J Gynecol Cancer. 2012 Jul; 22(6):960-7.
Kang BH, Siegelin MD, Plescia J, Raskett CM, Garlick DS, Dohi T, Lian JB, Stein GS, Languino LR, Altieri DC. Preclinical characterization of mitochondria-targeted small molecule hsp90 inhibitors, gamitrinibs, in advanced prostate cancer. Clin Cancer Res. 2010 Oct 1; 16(19):4779-88.
Torres MP, Ponnusamy MP, Chakraborty S, Smith LM, Das S, Arafat HA, Batra SK. Effects of thymoquinone in the expression of mucin 4 in pancreatic cancer cells: implications for the development of novel cancer therapies. Mol Cancer Ther. 2010 May; 9(5):1419-31.
Fiskus W, Rao R, Fernandez P, Herger B, Yang Y, Chen J, Kolhe R, Mandawat A, Wang Y, Joshi R, Eaton K, Lee P, Atadja P, Peiper S, Bhalla K. Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells. Blood. 2008 Oct 1; 112(7):2896-905.
Vasilevskaya IA, O'Dwyer PJ. 17-Allylamino-17-demethoxygeldanamycin overcomes TRAIL resistance in colon cancer cell lines. Biochem Pharmacol. 2005 Aug 15; 70(4):580-9.
Vasilevskaya IA, Rakitina TV, O'Dwyer PJ. Quantitative effects on c-Jun N-terminal protein kinase signaling determine synergistic interaction of cisplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines. Mol Pharmacol. 2004 Jan; 65(1):235-43.
Rakitina TV, Vasilevskaya IA, O'Dwyer PJ. Additive interaction of oxaliplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines results from inhibition of nuclear factor kappaB signaling. Cancer Res. 2003 Dec 15; 63(24):8600-5.
Luo J, Benovic JL. G protein-coupled receptor kinase interaction with Hsp90 mediates kinase maturation. J Biol Chem. 2003 Dec 19; 278(51):50908-14.